Agili c clinical trials

A total of 16 patients have been enrolled and undergone operations at European centers in the trial, the Oct 2, 2017 KFAR SABA, Israel, Oct. Results demonstrated the potential for cartilage regeneration and remodeling of the underlying Another recent breakthrough in osteoarthritis treatment, a device called Agili-C, is looking to be a better option for those thinking about knee replacement as we continue to support this research through getting involved with organizations, like the Arthritis Foundation and volunteer participation in clinical trials, the future of . Asia/Pacific, Yes. Cartilage or Osteochondral Defects in the Knee Up to Moderate Osteoarthritis, Device: Agili-C implant Procedure: SSOC Oct 3, 2017 CartiHeal said yesterday it launched an FDA investigational device exemption clinical study of its Agili-C implant for repairing cartilage, osteochondral defects and treating joint surface lesions. Dec 20, 2016 Agili-C™ was implanted in a series of clinical trials conducted in leading centers in Europe and Israel, in over 220 patients with cartilage lesions in the knee, ankle and great toe. Agili-C implant is a bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of focal articular cartilage and for osteochondral defects. 17 patients were enrolled and operated on during the first week of the study in 3 leading European centers. Patients suffering from isolated, single and focal cartilage or osteochondral defect at the knee joint are considered for study Agili-C™ implant is a CE marked, bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of articular cartilage and/or osteochondral defects. 2, 2017 /PRNewswire/ -- CartiHeal, developer of Agili-C, proprietary implants for the treatment of joint surface lesions, announced today the initiation of Its IDE clinical study. Results demonstrated the potential for cartilage regeneration and remodeling of the underlying Dec 21, 2017 Our pivotal study will include US and OUS centers, with the aim of evaluating the safety and effectiveness of Agili-C™ compared to current surgical standard of care in traumatic and arthritic lesions. South/Central America, Yes. In these trials the implant was used for the treatment of a wide spectrum of cartilage lesions, according to its CE Mark, from single Not available at all, Clinical Trial only, Commercially available in few countries, Commercially available in most countries, Commercially avaiable in all countries. The study is designed as prospective, multicenter, open-label, randomized and controlled. Australia, Yes Jan 9, 2017 The unicondylar implant is the next generation of the cylindrical shaped Agili-C™ implant which has been used successfully in close to 250 patients throughout Europe in clinical trials in the knee, ankle and great toe. As demonstrated in a series of preclinical studies, the new unicondylar implant Dec 27, 2016 Following its receipt of the CE Mark, Agili-C was implanted in more than 220 patients with cartilage lesions in the knee, ankle and/or great toe during a series of clinical trials conducted in Europe and Israel. In these trials the implant was used for the treatment of a wide spectrum of cartilage lesions, according to its CE Mark, from single Jan 9, 2017 The unicondylar implant is the next generation of the cylindrical shaped Agili-C™ implant which has been used successfully in close to 250 patients throughout Europe in clinical trials in the knee, ankle and great toe. Up to 50 patients are to be included in the study. Africa, Yes. The Agili-C™ implant will be implanted using the Agili-Kit™ surgical toolset which is designed for the precise preparation of sites in cartilage and osteochondral Condition or disease, Intervention/treatment. Europe, Yes. (Credit: CartiHeal). It will be Agili-C implant is a bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of focal articular cartilage and for osteochondral defects. As demonstrated in a series of preclinical studies, the new unicondylar Dec 27, 2016 Following its receipt of the CE Mark, Agili-C was implanted in more than 220 patients with cartilage lesions in the knee, ankle and/or great toe during a series of clinical trials conducted in Europe and Israel. North America, Yes

12s (27)